KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Net Cash Flow: 2020-2025

Historic Net Cash Flow for AbCellera Biologics (ABCL) over the last 6 years, with Sep 2025 value amounting to -$8.7 million.

  • AbCellera Biologics' Net Cash Flow rose 60.37% to -$8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.1 million, marking a year-over-year increase of 9.19%. This contributed to the annual value of $25.6 million for FY2024, which is 110.06% up from last year.
  • According to the latest figures from Q3 2025, AbCellera Biologics' Net Cash Flow is -$8.7 million, which was up 87.08% from -$67.6 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Net Cash Flow high stood at $247.0 million for Q2 2022, and its period low was -$408.8 million during Q3 2022.
  • Its 3-year average for Net Cash Flow is -$27.5 million, with a median of -$9.0 million in 2024.
  • The largest annual percentage gain for AbCellera Biologics' Net Cash Flow in the last 5 years was 342.17% (2021), contrasted with its biggest fall of 1,145.28% (2021).
  • Over the past 5 years, AbCellera Biologics' Net Cash Flow (Quarterly) stood at -$16.0 million in 2021, then soared by 188.59% to $14.2 million in 2022, then plummeted by 382.92% to -$40.2 million in 2023, then spiked by 179.28% to $31.8 million in 2024, then soared by 60.37% to -$8.7 million in 2025.
  • Its Net Cash Flow was -$8.7 million in Q3 2025, compared to -$67.6 million in Q2 2025 and $2.4 million in Q1 2025.